openPR Logo
Press release

Global Fragment-Based Drug Discovery Market Outlook 2031

08-15-2023 04:59 PM CET | Health & Medicine

Press release from: Transparency Market Research

๐—š๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—™๐—ฟ๐—ฎ๐—ด๐—บ๐—ฒ๐—ป๐˜-๐—•๐—ฎ๐˜€๐—ฒ๐—ฑ ๐——๐—ฟ๐˜‚๐—ด ๐——๐—ถ๐˜€๐—ฐ๐—ผ๐˜ƒ๐—ฒ๐—ฟ๐˜† ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ข๐˜‚๐˜๐—น๐—ผ๐—ผ๐—ธ ๐Ÿฎ๐Ÿฌ๐Ÿฏ๐Ÿญ

The global fragment-based drug discovery (FBDD) market is poised for remarkable growth, with a projected compound annual growth rate (CAGR) of 11.5% from 2023 to 2031. This innovative approach to early-stage drug development has gained substantial attention due to its ability to revolutionize the way we discover and develop new therapeutic agents. In 2022, the FBDD market was valued at US$ 795.4 million, and this value is expected to surge to over US$ 2.1 billion by the end of 2031.

๐—ฅ๐—ฒ๐—พ๐˜‚๐—ฒ๐˜€๐˜ ๐—ณ๐—ผ๐—ฟ ๐—ฎ ๐˜€๐—ฎ๐—บ๐—ฝ๐—น๐—ฒ ๐—ผ๐—ณ ๐˜๐—ต๐—ถ๐˜€ ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ฟ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—ฎ๐˜ (๐—จ๐˜€๐—ฒ ๐—–๐—ผ๐—ฟ๐—ฝ๐—ผ๐—ฟ๐—ฎ๐˜๐—ฒ ๐— ๐—ฎ๐—ถ๐—น ๐—œ๐—ฑ ๐—ณ๐—ผ๐—ฟ ๐—ค๐˜‚๐—ถ๐—ฐ๐—ธ ๐—ฅ๐—ฒ๐˜€๐—ฝ๐—ผ๐—ป๐˜€๐—ฒ) -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741&utm_source=OpenPR_Ajay&utm_medium=OpenPR

๐—”๐—ฑ๐˜ƒ๐—ฎ๐—ป๐˜๐—ฎ๐—ด๐—ฒ๐˜€ ๐—ผ๐—ณ ๐—™๐—•๐——๐——: ๐—›๐—ถ๐—ด๐—ต ๐—›๐—ถ๐˜ ๐—ฅ๐—ฎ๐˜๐—ฒ๐˜€ ๐—ฎ๐—ป๐—ฑ ๐—˜๐—ป๐—ต๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฑ ๐—–๐—ต๐—ฒ๐—บ๐—ถ๐—ฐ๐—ฎ๐—น ๐——๐—ถ๐˜ƒ๐—ฒ๐—ฟ๐˜€๐—ถ๐˜๐˜†

Fragment-based drug discovery has become a powerful tool in the pharmaceutical industry due to its unique advantages. Unlike traditional high-throughput screening methods, FBDD involves testing small, low molecular weight fragments as starting points for drug development. This approach offers several benefits, including increased chemical diversity, higher hit rates, and the ability to target challenging proteins that were once considered difficult to address.

The higher hit rates associated with FBDD are attributed to its screening strategy. By focusing on simple chemical structures in the form of small fragments, FBDD increases the likelihood of interactions with target proteins. As a result, more potential lead compounds are identified, streamlining the drug discovery process.

๐—”๐—ฝ๐—ฝ๐—น๐—ถ๐—ฐ๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ถ๐—ป ๐—ง๐—ต๐—ฒ๐—ฟ๐—ฎ๐—ฝ๐—ฒ๐˜‚๐˜๐—ถ๐—ฐ ๐—”๐—ฟ๐—ฒ๐—ฎ๐˜€: ๐—”๐—ฑ๐—ฑ๐—ฟ๐—ฒ๐˜€๐˜€๐—ถ๐—ป๐—ด ๐—–๐—ผ๐—บ๐—ฝ๐—น๐—ฒ๐˜… ๐——๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ๐˜€

One of the standout features of FBDD is its versatility across various therapeutic areas. In the field of oncology, for instance, FBDD has demonstrated immense potential in targeting specific cancer-associated proteins. Researchers have utilized this approach to identify small molecule fragments that bind to oncogenic proteins involved in tumor growth.

Furthermore, FBDD's success extends to the central nervous system (CNS) disorders. Leading biotech companies have applied FBDD to target proteins associated with neurodegenerative diseases like Alzheimer's and Parkinson's. By leveraging FBDD's capabilities, they aim to develop innovative therapies for these challenging conditions.

๐—•๐˜‚๐˜† ๐˜๐—ต๐—ถ๐˜€ ๐—ฃ๐—ฟ๐—ฒ๐—บ๐—ถ๐˜‚๐—บ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ | ๐—œ๐—บ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฎ๐˜๐—ฒ ๐——๐—ฒ๐—น๐—ถ๐˜ƒ๐—ฒ๐—ฟ๐˜† ๐—”๐˜ƒ๐—ฎ๐—ถ๐—น๐—ฎ๐—ฏ๐—น๐—ฒ ๐—ฎ๐˜ -

https://www.transparencymarketresearch.com/checkout.php?rep_id=4741<ype=S&utm_source=OpenPR_Ajay&utm_medium=OpenPR

๐—˜๐—ณ๐—ณ๐—ถ๐—ฐ๐—ถ๐—ฒ๐—ป๐—ฐ๐˜† ๐—ฎ๐—ป๐—ฑ ๐—ฆ๐—ฝ๐—ฒ๐—ฒ๐—ฑ ๐—ถ๐—ป ๐——๐—ฟ๐˜‚๐—ด ๐——๐—ถ๐˜€๐—ฐ๐—ผ๐˜ƒ๐—ฒ๐—ฟ๐˜†

The fragment screening segment is a major driver of the FBDD market, as it offers both efficiency and speed in the drug discovery process. This segment includes services such as library screening, biophysical screening (NMR, X-ray crystallography), and computational screening.

Fragment screening enables exploration of a vast chemical space using small fragments that can access unique binding sites on target proteins. This not only leads to the discovery of novel binding modes but also provides crucial insights into atomic-level interactions, guiding the optimization process effectively. Moreover, screening smaller libraries of fragments is faster and more cost-effective than traditional high-throughput screening, resulting in a more streamlined drug discovery journey.

๐—ฅ๐—ถ๐˜€๐—ฒ ๐—ถ๐—ป ๐——๐—ฒ๐—บ๐—ฎ๐—ป๐—ฑ ๐—ณ๐—ผ๐—ฟ ๐—›๐—ถ๐—ด๐—ต ๐—ฆ๐—ฝ๐—ฒ๐—ฐ๐—ถ๐—ณ๐—ถ๐—ฐ๐—ถ๐˜๐˜† & ๐—ฆ๐—ฒ๐—ป๐˜€๐—ถ๐˜๐—ถ๐˜ƒ๐—ถ๐˜๐˜† ๐—ถ๐—ป ๐—–๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต & ๐——๐—ฟ๐˜‚๐—ด ๐——๐—ฒ๐˜ƒ๐—ฒ๐—น๐—ผ๐—ฝ๐—บ๐—ฒ๐—ป๐˜

In terms of application, oncology is expected to dominate the FBDD market during the forecast period. This is primarily due to the increasing focus on cancer research and drug development. Prominent pharmaceutical companies are investing heavily in oncology-focused FBDD research and forming collaborations with specialized FBDD providers to identify novel drug candidates for various oncology targets.

๐—ฅ๐—ฒ๐—พ๐˜‚๐—ฒ๐˜€๐˜ ๐—ณ๐—ผ๐—ฟ ๐—ฐ๐˜‚๐˜€๐˜๐—ผ๐—บ๐—ถ๐˜‡๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ผ๐—ณ ๐˜๐—ต๐—ถ๐˜€ ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต ๐—ฟ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜ ๐—ฎ๐˜ -

https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=4741&utm_source=OpenPR_Ajay&utm_medium=OpenPR

๐—š๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—Ÿ๐—ฒ๐—ฎ๐—ฑ๐—ฒ๐—ฟ๐˜€ ๐—ฎ๐—ป๐—ฑ ๐—œ๐—ป๐—ป๐—ผ๐˜ƒ๐—ฎ๐˜๐—ผ๐—ฟ๐˜€ ๐—ถ๐—ป ๐—™๐—•๐——๐——

Key players in the FBDD market are making significant investments in research and development, as well as collaborative efforts, to enhance their market presence. Companies such as Alveus Pharmaceuticals Pvt. Ltd., Astex Pharmaceuticals, Charles River Laboratories International, Inc., and Evotec AG are at the forefront of FBDD innovation. These players have demonstrated their commitment to advancing drug discovery by leveraging FBDD's unique advantages.

๐—ฅ๐—ฒ๐—ด๐—ถ๐—ผ๐—ป๐—ฎ๐—น ๐——๐˜†๐—ป๐—ฎ๐—บ๐—ถ๐—ฐ๐˜€

North America remains a dominant force in the FBDD market, driven by substantial investments in research and development, well-established infrastructure, and robust healthcare systems. The region's proactive adoption of technological advancements positions it as a leader in implementing FBDD techniques.

Asia Pacific is witnessing a surge in demand for FBDD services, driven by increased investment in healthcare infrastructure and a strong emphasis on quality management. Countries such as China and Japan are emerging as potential markets for FBDD, signaling a growing interest in innovative drug discovery approaches.

๐— ๐—ผ๐—ฟ๐—ฒ ๐—ง๐—ฟ๐—ฒ๐—ป๐—ฑ๐—ถ๐—ป๐—ด ๐—ฅ๐—ฒ๐—ฝ๐—ผ๐—ฟ๐˜๐˜€ ๐—ฏ๐˜† ๐—ง๐—ฟ๐—ฎ๐—ป๐˜€๐—ฝ๐—ฎ๐—ฟ๐—ฒ๐—ป๐—ฐ๐˜† ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต -

Congestive Heart Failure Drugs Market

https://www.globenewswire.com/en/news-release/2023/04/13/2646759/0/en/Congestive-Heart-Failure-Drugs-Market-Size-to-Cross-USD-13-5-Bn-Revenue-by-2031-TMR-Study.html

Cardiotonic Agents Market

https://www.globenewswire.com/en/news-release/2023/04/03/2639893/0/en/Cardiotonic-Agents-Market-Size-to-Reach-USD-4-5-Bn-by-2031-Due-to-the-Rise-in-Prevalence-of-Cardiovascular-Diseases-TMR-Study.html

๐—”๐—ฏ๐—ผ๐˜‚๐˜ ๐—จ๐˜€ ๐—ง๐—ฟ๐—ฎ๐—ป๐˜€๐—ฝ๐—ฎ๐—ฟ๐—ฒ๐—ป๐—ฐ๐˜† ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐˜ ๐—ฅ๐—ฒ๐˜€๐—ฒ๐—ฎ๐—ฟ๐—ฐ๐—ต

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, providesย custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

๐—–๐—ผ๐—ป๐˜๐—ฎ๐—ฐ๐˜ ๐—จ๐˜€

Nikhil Sawlani

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Fragment-Based Drug Discovery Market Outlook 2031 here

News-ID: 3165496 • Views: โ€ฆ

More Releases from Transparency Market Research

Sterile Injectable Drugs Market Poised to Reach USD 909.4 Bn by 2031, Amid Rising Chronic Disease Burden and Growing Demand for Cost-Effective Injectable Therapies | TMR
Sterile Injectable Drugs Market Poised to Reach USD 909.4 Bn by 2031, Amid Risin โ€ฆ
The Sterile Injectable Drugs Market continues to demonstrate strong momentum as global demand for highly effective, fast-acting, and contamination-free injectable therapies rises. According to the latest analysis, the market-valued at US$ 584.6 Bn in 2022-is projected to grow at a CAGR of 4.9% from 2023 to 2031, reaching US$ 909.4 Bn by the end of 2031. The surge in prevalence of chronic diseases, increased adoption of cost-effective generic injectables, andโ€ฆ
Sterilization Equipment Market Set to Reach USD 27.1 Bn by 2031 Amid Rising HAIs and Stringent Global Sterility Regulations | TMR
Sterilization Equipment Market Set to Reach USD 27.1 Bn by 2031 Amid Rising HAIs โ€ฆ
The global sterilization equipment market, valued at US$ 13.8 Bn in 2022, is projected to grow at a CAGR of 7.9% from 2023 to 2031, reaching a value of US$ 27.1 Bn by the end of 2031. This growth trajectory reflects expanding surgical volumes worldwide, an increasing focus on infection control in healthcare settings, and the introduction of stricter guidelines regulating sterilization standards across major regions. Examine key highlights and takeawaysโ€ฆ
Sterilization Services Market to Reach USD 10.1 Billion by 2031, Driven by Rising Healthcare Demand and Technological Advancements | TMR
Sterilization Services Market to Reach USD 10.1 Billion by 2031, Driven by Risin โ€ฆ
The global Sterilization Services Market was valued at US$ 4.6 billion in 2022. According to the latest industry assessment, the market is projected to expand at a CAGR of 9.5% from 2023 to 2031, ultimately reaching US$ 10.1 billion by the end of 2031. This strong upward trajectory reflects the accelerating demand for sterilization in healthcare and pharmaceutical environments, rapid advancements in sterilization methodologies, and the expansion of medical facilitiesโ€ฆ
Synthetic Fiber Market: Transforming Global Textiles, Mobility, and Industrial Manufacturing Through 2034
Synthetic Fiber Market: Transforming Global Textiles, Mobility, and Industrial M โ€ฆ
The Global Synthetic Fiber Market continues to demonstrate steady growth, supported by expanding applications in apparel, automotive manufacturing, home furnishings, construction, filtration, and technical textiles. Valued at US$ 66.9 Bn in 2023, the industry is projected to grow at a CAGR of 4.8% from 2024 to 2034, ultimately reaching US$ 111.9 Bn by 2034. With rapid urbanization, evolving consumer lifestyles, and increasing adoption of high-performance materials, synthetic fibers remain aโ€ฆ

All 5 Releases


More Releases for FBDD

Fragment-Based Drug Discovery Market to Reach USD 3.2 Billion by 2035, Driven by โ€ฆ
The global Fragment-based Drug Discovery (FBDD) Market is set for robust growth, projected to expand from US$ 1.1 billion in 2024 to US$ 3.2 billion by 2035, registering a strong CAGR of 10.6%, according to the latest market analysis. Increasing adoption of fragment-based techniques in drug design, the emergence of innovative fragment libraries, and expanding applications in oncology and central nervous system (CNS) disorders are key forces propelling the marketโ€ฆ
Fragment-Based Drug Discovery Market Size, Share, Growth Forecast 2023-2032
The Fragment-Based Drug Discovery (FBDD) market has been gaining traction in recent years, emerging as a transformative approach in the pharmaceutical and biotechnology industries. The market size for FBDD was valued at USD 1.1 billion in 2022 and is projected to reach USD 3.8 billion by 2032, growing at a remarkable compound annual growth rate (CAGR) of 14.0% from 2023 to 2032. This article delves into the competitive landscape, futureโ€ฆ
Fragment Based Drug Discovery Market Set to Reach USD 2.1 billion by 2031, Surgi โ€ฆ
The fragment-based drug discovery market encompasses a wide range of stakeholders, including pharmaceutical companies, contract research organizations (CROs), academic institutions, and technology providers. FBDD offers several advantages over traditional high-throughput screening approaches, including the ability to sample chemical space more comprehensively, target protein-protein interactions, and access novel binding sites that may be challenging to target with larger, more complex molecules. As a result, FBDD has gained traction in the pharmaceuticalโ€ฆ
Fragment-Based Drug Discovery Market Research Insight 2022| Industry Development โ€ฆ
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Fragment-Based Drug Discovery Market by (technique (x-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), service (library screening, fragment screening and fragment optimization), End-users (hospitals, industry players and non-industry players) - Market Outlook and Industry Analysis 2030" Get Demo Sample copy of Fragment-Based Drug Discovery Market Report at: https://www.insightaceanalytic.com/request-sample/1175 Over theโ€ฆ
Fragment-based Drug Discovery Market Key Trends & Industry Forecast 2015 - 2023
38.4% of the global fragment-based drug discovery market was collectively held by its top three players in 2014. Astex Pharmaceuticals, Charles River Laboratories International, Inc., and Sygnature Discovery were the key contributors to the market revenue at the time and are expected to retain their lead in the near future. A new research report released by Transparency Market Research states that with 52.3% of the global fragment-based drug discovery marketโ€ฆ
Global Fragment-Based Drug Discovery (FBDD) Market Analysis: Services, End Users โ€ฆ
The global fragment-based drug discovery market is estimated to reach USD 650 Million in 2020, growing at a CAGR of 10.6% from 2016 to 2020. Increasing adoption of fragment-based screening programs by most of the major pharmaceutical companies, increasing availability of more assay options in research departments of most pharmaceutical and biotechnology companies for high hit rates of fragment-based screens are the major drivers of the global fragment-based drug discoveryโ€ฆ